- Retail Earnings in Focus Ahead of Shopping Season
- Apple Surpasses Nokia as Top Handset Maker by Profit
- In This Relay-Race Market, Who Gets Baton Next?
- Workers Staying Put at Their Jobs as Jobless Surges
- Three Things the US Can Do To Stop the Dollar's Decline
- Toll Brothers: More Contracts Signed, but Sales Down
- Ponzi Proceeds: Bidding on Madoff's Toys
- Bear Stearn Fund Managers Not Guilty on All Counts
- Commodity ETFs: Returns May Not Match Expectations
- Beware of 'Trampling Effect' When Market Tops: Manager
- Gold Heading to $1150: Art Hogan
- Starbucks Brews Up Growth
- Farr: An Extended Period—No Fat Lady in Sight
- More Upside if S&P Passes This Number: Market Pro
- Murdoch Lashes Out At Google
- Fighting The Flu Vaccine Critics
- Nov. 10: Unusual Volume Leaders
- Shadow Inventory Dwarfs Loan Mods
MOST SHARED
- Herbalife Vs. Hedge Funds
- Apple Surpasses Nokia as Top Cellphone Maker by Profits
- Gold Heading to $1150: Art Hogan
- Adobe Cuts 680 Jobs, to Take Charge
- Toll Brothers: More Contracts Signed, but Sales Down
- Cramer Jeers J&J, Applauds Abbott
- US Becomes Top Country Brand Under Obama: Survey
- Starbucks Brews Up Growth
Text Size 
Pharmaceutical giant Merck [MRK
Loading...
()
] said quarterly earnings rose as booming sales of newer medicines offset declines in older products, and said it plans to seek U.S. approval in 2009 for a migraine-headache treatment now entering late-stage trials.
Merck, which on April 12 preannounced the quarterly earnings trends, posted first-quarter net earnings of $1.7 billion, or 78 cents a share, compared with $1.52 billion, or 69 cents a share, a year earlier.
Merck earned 84 cents a share excluding restructuring charges, matching its forecast of last week.
Company sales rose 7% to $5.8 billion, fueled by surging revenue from its newer cholesterol fighters Zetia and Vytorin, new vaccines and the new Januvia diabetes treatment, as well as from strong sales growth of asthma drug Singulair and treatments for high blood pressure.
Merck said its migraine drug MK-0974, a so-called calcitonin gene-related peptide (CGRP) antagonist, is now entering Phase III trials. Data from mid-stage trials of the product will be unveiled at a medical meeting in June, the drugmaker said.
Combined sales of Vytorin and Zetia, which are marketed in partnership with Schering-Plough [SGP
Loading...
()
], grew 47% to $1.2 billion. Singulair sales jumped 25 percent to $1 billion, while combined sales of hypertension drugs Cozaar and Hyzaar rose 14 percent to $798 million. Januvia, a pill introduced in October, posted quarterly sales of $87 million.
Total sales of vaccines -- including Gardasil to prevent cervical cancer and Rotateq to protect against rotavirus infections in young children -- more than tripled to $903 million.
Print
Email
- Vote and suggest your own, and remember--there's a fine line between a hero and a zero.
- If you are lucky enough to have money and the time, this is a great time to see America, says CNBC's Jane Wells.
- What’s powering your microwave, fridge and computer? Part of it is fuel from Russian nuclear weapons. The NYT reports.
- One author sees lessons for you in Disney’s recent Makeover of Mickey Mouse: “Nice” doesn’t always win.
- With 123 years of history, slogans and commercials, Coca-Cola is the most recognized brand on earth.
- The opening of a virtual pet store in “World of Warcraft” could prove a cash bonanza for Activision-Blizzard.
Data is a real-time snapshot *Data is delayed at least 15 minutes